Literature DB >> 26998124

Curative effect of the recent photofrin photodynamic adjuvant treatment on young patients with advanced colorectal cancer.

B O Sun1, Wei Li1, Ning Liu2.   

Abstract

Advanced colorectal cancer has a high mortality rate and conventional treatments have poor therapeutic effects. The aim of the present study was to analyze the recent curative effect and adverse reaction of photofrin photodynamic adjuvant treatment on young patients with advanced colorectal cancer. A total of 23 patients with advanced colorectal cancer who had accepted semiconductor laser photodynamic adjuvant treatment were selected as the observation group. In addition, 30 patients who had accepted concurrent radiotherapy and chemotherapy during the same period served as the control group. The observation group received photofrin (2 mg/kg) intravenously in 100 ml of 5% glucose, followed by the introduction of the endoscopic optical fiber to deliver laser radiation with an intensity of 630 nm wavelength pulse power. After 2 days, necrotic tissues were removed and irradiation of the original or new tumor lesions was performed and necrotic tissues were removed. The total effective rate and survival time was higher and the length of hospital stay was shorter in the observation group in comparison with the control group. The differences were statistically significant (P<0.05). The number of patients in the control and observation groups with symptoms of hematochezia, change in bowel habit, intestinal stimulation and incomplete intestinal obstruction were reduced. Additionally, the reduced ratio of the observation group was significantly increased in comparison with the control group (P<0.05). The adverse reaction rate of the observation group was lower than that of the control group and this difference was also statistically significant (P<0.05). In conclusion, use of photodynamic treatment for young patients with advanced colorectal cancer can effectively improve the clinical symptoms and reduce complications.

Entities:  

Keywords:  advanced colorectal cancer; hematochezia; intestinal obstruction; photodynamic treatment; photofrin

Year:  2016        PMID: 26998124      PMCID: PMC4774444          DOI: 10.3892/ol.2016.4179

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

The incidence and mortality rates of advanced colorectal cancer have been on the increase in recent years. Data presented at the 8th Shanghai International Settlement rectal cancer forum in 2012 demonstrated that the incidence of colorectal cancer is the highest in western developed countries with regard to malignancies and ranks fourth in China. The mortality rate ranks second in developed countries and sixth in China (1). The pathogenesis of the disease is associated with genetic and long-term chronic intestinal inflammation (2). Early clinical symptoms are atypical and 40–50% patients have been diagnosed with metastasis due to a lack of specific screening tools (3). The degree of malignancy is higher especially for young patients (4). Conventional treatments such as surgical resection, radiotherapy and chemotherapy have poor therapeutic effects and considerable side effects (5). Microwave and high power laser treatments can increase severe complications including intestinal bleeding, esophageal mediastinal fistula or esophagotracheal fistula (6,7). As a means of local tumor ablation, photodynamic therapy (PDT) has been developing rapidly in recent years. PDT has a slight effect on normal tissues, but can kill tumor cells selectively and repeated treatment improves the therapeutic effect (8). PDT is beneficial in the treatment of colorectal cancer, it does not cause cicatricial stenosis. In addition, it can significantly improve the quality of life of patients with cancer and extend their life span (9,10). PDT has been widely applied in the treatment of throat, bladder, lung, esophageal, and gastric cancer (11). In the present study, semiconductor laser PDT was used to treat 23 young patients with advanced colorectal cancer and its importance for the clinical treatment of advanced colorectal cancer was assessed.

Patients and methods

Patients and control

Twenty-three patients with advanced colorectal cancer who had accepted semiconductor laser PDT were chosen between September, 2010 and February, 2014 in The First People's Hospital of Xuzhou as the observation group. The patients did not undergo surgery, could not be relieved of the complete or incomplete obstruction and experienced relapse after accepting radiotherapy, chemotherapy and surgical resection. Of the 23 patients, 16 were men and 7 were women, with an age range of 23–58 years with a median age of 41.9 years. Of the 23 patients, 21 had rectal cancer and 2 had sigmoid carcinoma. Advanced colorectal cancer in the 23 patients was confirmed pathologically, 10 patients were in Dukes C stage and 13 patients were in D stage. Seven patients had liver metastasis and 16 patients were out of control after accepting to undergo chemotherapy. Four patients had tumor recurrence after surgical resection and three patients had tumor recurrence after radiotherapy. Hematochezia was observed in 6 patients, a change in bowel habit and intestinal stimulation was observed in 13 patients, and 4 patients exhibited incomplete intestinal obstruction. Thirty patients who accepted concurrent radiotherapy and chemotherapy served as the controls. Of the 30 patients, 21 were men and 9 were women, with an age range of 27–56 years, and a median age of 41.9 years. The study was approved by the ethics committee of The First People's Hospital of Xuzhou. Written informed consent was provided by the patients.

PDT

Laser therapy was performed using Diomed 630 (British Laser Instrument Co., Ltd., Diomed, Cambridge, UK) with an output of 630 nm wavelength pulse power. The optical fibers included were column-shaped and flat cut fibers. The length of the terminal of the column-shaped fiber was 2–5 cm and the photosensitizer was photofrin (Canadian Pharmaceutical Co., Ltd., Québec, Canada). Photofrin at a final concentration of 2 mg/kg was administered to the patients intravenously in 100 ml of 5% glucose. After 48 h, laser irradiation at 630 nm was delivered through a flat cut optical fiber. For different lesion ranges, different lengths of column-shaped fibers were used. The irradiation dose of different types set in the machine was in accordance with differences of the tumor length in the cavity. Normally, 1–3 segments were irradiated each time and the irradiating time was ~12 min, with an energy density of 200 J/cm2. Each segment was interlinked when treated, at least exceeding 0.5 cm of the tumor boundary, leading to the illumination range completely covering the tumor area. The necrotic tissues were removed endoscopically after 2 days and repeated irradiations were performed at the original tumor and new tumor sites to improve the therapeutic effect. The patients underwent enteroscopic examination after one month to monitor the therapeutic effect of the treatment. It was identified that 5 patients used intestinal stent after laser radiation.

Curative effect

The general standards to classify colon cancer in the present study were: i) complete response (CR), where the tumor completely disappeared, tissue histopathology was negative and this condition lasted ≥1 month; ii) partial response (PR), where tumor maximum diameter and vertical diameter or the tumor height narrowed >50% and this condition lasted ≥1 month; iii) mild response, where the tumor narrowed <50% and this condition lasted ≥1 month; iv) no response, no change or enlargement of the tumor.

Statistical analysis

The SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used to analyze the results. Data were presented as mean ± standard deviation. Comparisons between groups was performed by t-test and Chi-square test. P<0.05 was considered to indicate a statistically significant difference.

Results

Clinical efficacy of the PDT treatment

The patient age, gender and stages of cancer were not significantly different between patients in the observation and control groups (P>0.05). The total effective rate of the observation group was significantly higher when compared with that of the control group. An increased survival time and decreased length of hospital stay was also identified in patients of the observation group in comparison with those of the control group (Table I).
Table I.

Clinical efficacy of the treatment.

GroupsPatientsCRPRMRNRTotal effective rateSurvival time (months)Length of hospital stay
Control3025518403.01±1.1219.72±5.21
Observation23268769.576.23±1.6513.47±4.46
t2.3413.8462.212
P-value0.0350.0130.036

CR, complete response; PR, partial response; MR, mild response; NR, no response.

Clinical symptoms relieved in patients who had received PDT

The number of patients exhibiting symptoms including hematochezia, change in bowel habits, intestinal stimulation and incomplete intestinal obstruction were distributed similarly prior to treatment in the two groups. However, following PDT treatment, the number of patients exhibiting these symptoms became reduced in the observation group. Conventional treatments such as radiotherapy and chemotherapy did not reduce the number of patients with these symptoms, as is evident in the control group. Additionally, the reduced ratio in the observation group was significantly higher than that of the control group (χ2=2.094, P=0.041; Table II).
Table II.

PDT treatment relieved the clinical symptoms.

Before treatmentAfter treatment


GroupsPatientsHematocheziaBowel habits and intestinal stimulationIncomplete intestinal obstructionHematocheziaBowel habits and intestinal stimulationIncomplete intestinal obstruction
Control3091747123
Observation236134372

PDT, photodynamic therapy.

Adverse reaction rate reduced in PDT treatment

The adverse reaction rate in the observation group was significantly reduced compared to that of the control group (χ2=2.997, P=0.031; Table III).
Table III.

Adverse reaction rate reduced in PDT treatment.

GroupsPatientsIntestinal, rectovesical fistula or rectovaginal fistulaPhotosensitive dermatitisLower gastrointestinal hemorrhageMyelosupression, liver and kidney toxicityOthers
Control3053421
Observation232130

PDT, photodynamic therapy.

Discussion

PDT comprises a photosensitizer, laser and dioxygen, and each substance is harmless to cells (12). The rapid development of the photosensitizer and laser irradiation systems has led to PDT gradually becoming a new method used in the treatment of various types of tumor (13). The biological mechanism of PDT has been fully understood. The basic principle is the photochemistry principle of the photodynamic laser, which utilizes a laser of specific wavelength to activate the photosensitizer remaining in the tumor tissues. Thus, the photosensitizer operates with oxygen in tumor tissues, producing robust radicals from singlet oxygen. Consequently, colon cancer cells are attacked by oxidation, subsequently killing tumor cells (14,15). PDT has gradually become an anticancer strategy employed in the treament of colorectal cancer (16). Compared with traditional anticancer strategies such as surgery, radiotherapy and chemotherapy, PDT has numerous inherent advantages including accurately positioning target tumor tissues, relatively non-invasive treatment, non-requirement of repeated drug administration, relative ease of operation, fewer side-effects, little trauma, low toxicity, wide range of applications, protecting appearance and important organ functions, less irradiation to the blind region, relatively steady curative effect, selective damage to tumor tissues and suitability for colon cancer patients of all ages and stages (17–19). Previous studies focusing on progressive stage colon cancer have demonstrated that the PR rate of patients is 44% and the CR rate is 35% (20,21). The total effective rate of PDT for patients with advanced colon cancer to control bleeding, relieve pain and intestinal obstruction reached 70% (22,23). In this study, the total effective rate of the observation group was significantly higher than that of the control group. The former's survival time was also significantly higher and the length of hospital stay was significantly reduced. Furthermore, it was identified that the symptoms of patients in the observation group with hematochezia, change in bowel habits, intestinal stimulation and incomplete intestinal obstruction were alleviated and the adverse reaction rate was markedly decreased. A minor adverse reaction was primatily skin photosensitivity following laser irradiation. The curative effect of the photosensitizer with laser irradiation treatment was therefore more beneficial than conventional treatments. Thus, photofrin photodynamic treatment on young patients with advanced colorectal cancer can be used as an adjuvant treatment option and has relatively great clinical value for promotion.
  23 in total

1.  Temoporfin photodynamic therapy in advanced hilar ductal carcinoma: A promising endoscopic modality.

Authors:  Nikhil A Kumta; Ketisha DeRoche; Michel Kahaleh
Journal:  Hepatology       Date:  2015-09-01       Impact factor: 17.425

2.  Photosensitizer-Loaded pH-Responsive Hollow Gold Nanospheres for Single Light-Induced Photothermal/Photodynamic Therapy.

Authors:  Meng Yu; Fang Guo; Jinping Wang; Fengping Tan; Nan Li
Journal:  ACS Appl Mater Interfaces       Date:  2015-08-10       Impact factor: 9.229

3.  Photodynamic therapy for nonmelanoma skin cancer of the genital area: our experience.

Authors:  Catharina Fluehler; Claudia Colli; Alessandro Gatti; Giusto Trevisan
Journal:  Acta Dermatovenerol Croat       Date:  2015       Impact factor: 1.256

4.  Protoporphyrin IX-loaded magnetoliposomes as a potential drug delivery system for photodynamic therapy: Fabrication, characterization and in vitro study.

Authors:  Harun Basoglu; Mehmet Dincer Bilgin; Mustafa Muammer Demir
Journal:  Photodiagnosis Photodyn Ther       Date:  2016-01-02       Impact factor: 3.631

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  131I-Zn-Chlorophyll derivative photosensitizer for tumor imaging and photodynamic therapy.

Authors:  Kasim Ocakoglu; Ozge Er; Guven Kiyak; Fatma Yurt Lambrecht; Cumhur Gunduz; Cagla Kayabasi
Journal:  Int J Pharm       Date:  2015-07-28       Impact factor: 5.875

7.  Antimicrobial efficacy of photodynamic therapy, Nd:YAG laser and QMiX solution against Enterococcus faecalis biofilm.

Authors:  Ivona Bago Jurič; Vanda Plečko; Ivica Anić; Sanja Pleško; Suzana Jakovljević; Jean Paul Rocca; Etienne Medioni
Journal:  Photodiagnosis Photodyn Ther       Date:  2015-07-29       Impact factor: 3.631

Review 8.  A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.

Authors:  Hiroshi Maeda; Kenji Tsukigawa; Jun Fang
Journal:  Microcirculation       Date:  2016-04       Impact factor: 2.628

Review 9.  Quinones as photosensitizer for photodynamic therapy: ROS generation, mechanism and detection methods.

Authors:  M Rajendran
Journal:  Photodiagnosis Photodyn Ther       Date:  2015-08-01       Impact factor: 3.631

10.  A comparison of the antibacterial activity of the two methods of photodynamic therapy (using diode laser 810 nm and LED lamp 630 nm) against Enterococcus faecalis in extracted human anterior teeth.

Authors:  Mohammad Asnaashari; Seyed Masoud Mojahedi; Zahra Asadi; Saranaz Azari-Marhabi; Alireza Maleki
Journal:  Photodiagnosis Photodyn Ther       Date:  2015-08-01       Impact factor: 3.631

View more
  10 in total

1.  Effects of Radiotherapy in Combination With Irinotecan and 17-AAG on Bcl-2 and Caspase 3 Gene Expression in Colorectal Cancer Cells.

Authors:  Mahnaz Ebrahimpour; Mahshid Mohammadian; Bagher Pourheydar; Zhino Moradi; Zhaleh Behrouzkia
Journal:  J Lasers Med Sci       Date:  2022-02-28

2.  Highly Efficient Water-Soluble Photosensitizer Based on Chlorin: Synthesis, Characterization, and Evaluation for Photodynamic Therapy.

Authors:  Yue Sun; Xiaorui Geng; Yihui Wang; Xiaomin Su; Ruyin Han; Jiangyue Wang; Xinyan Li; Pan Wang; Kun Zhang; Xiaobing Wang
Journal:  ACS Pharmacol Transl Sci       Date:  2021-02-04

3.  Tumor Size-Dependent Anticancer Efficacy of Chlorin Derivatives for Photodynamic Therapy.

Authors:  Ji-Eun Chang; Yang Liu; Tae Heon Lee; Woo Kyoung Lee; Il Yoon; Kwhanmien Kim
Journal:  Int J Mol Sci       Date:  2018-05-29       Impact factor: 5.923

Review 4.  Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future.

Authors:  Razan Alzeibak; Tatiana A Mishchenko; Natalia Y Shilyagina; Irina V Balalaeva; Maria V Vedunova; Dmitri V Krysko
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

Review 5.  Nanoparticle-Mediated Delivery Systems in Photodynamic Therapy of Colorectal Cancer.

Authors:  Nokuphila Winifred Nompumelelo Simelane; Heidi Abrahamse
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 5.923

Review 6.  Porphyrin/Chlorin Derivatives as Promising Molecules for Therapy of Colorectal Cancer.

Authors:  Fatima Dandash; David Y Leger; Mona Diab-Assaf; Vincent Sol; Bertrand Liagre
Journal:  Molecules       Date:  2021-11-30       Impact factor: 4.411

Review 7.  Photodynamic diagnosis and photodynamic therapy of colorectal cancer in vitro and in vivo.

Authors:  Nokuphila Winifred Nompumelelo Simelane; Cherie Ann Kruger; Heidi Abrahamse
Journal:  RSC Adv       Date:  2020-11-14       Impact factor: 4.036

Review 8.  Porphyrin photosensitizers in photodynamic therapy and its applications.

Authors:  Jiayuan Kou; Dou Dou; Liming Yang
Journal:  Oncotarget       Date:  2017-08-11

9.  Evaluation of miR-21 Inhibition and its Impact on Cancer Susceptibility Candidate 2 Long Noncoding RNA in Colorectal Cancer Cell Line.

Authors:  Miganoosh Simonian; Mohammadreza Sharifi; Reza Nedaeinia; Meysam Mosallaie; Sharifeh Khosravi; Amir Avan; Majid Ghayour-Mobarhan; Hadi Bagheri; Rasoul Salehi
Journal:  Adv Biomed Res       Date:  2018-01-30

Review 10.  Recent Advances in Porphyrin-Based Inorganic Nanoparticles for Cancer Treatment.

Authors:  Hanieh Montaseri; Cherie Ann Kruger; Heidi Abrahamse
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.